NASDAQ: JANXJanux Therapeutics Inc Stock
$24.90-0.66 (-2.58%)
Updated Jun 13, 2025
JANX Price
$24.90
Fair Value Price
$4.41
Market Cap
$1.47B
52 Week Low
$22.48
52 Week High
$71.71
P/E
-18.44x
P/B
1.46x
P/S
178.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.34M
Earnings
-$77.74M
Gross Margin
100%
Operating Margin
-832.71%
Profit Margin
-832.7%
Debt to Equity
0.04
Operating Cash Flow
-$46M
Beta
1.52
Next Earnings
Jun 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A
JANX Overview
Janux Therapeutics Incorporated is a biopharma developing therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients with cancer. Its lead TRACTr product candidates target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company's EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. Janux Therapeutics was incorporated in 2017 and is headquartered in La Jolla, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine JANX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
JANX
Ranked#373 of 464
Ranked#373 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important JANX news, forecast changes, insider trades & much more!
JANX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how JANX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JANX ($24.90) is overvalued by 464.61% relative to our estimate of its Fair Value price of $4.41 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
JANX ($24.90) is not significantly undervalued (464.61%) relative to our estimate of its Fair Value price of $4.41 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
JANX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more JANX due diligence checks available for Premium users.
Valuation
JANX fair value
Fair Value of JANX stock based on Discounted Cash Flow (DCF)
Price
$24.90
Fair Value
$4.41
Overvalued by
464.61%
JANX ($24.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
JANX ($24.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
JANX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
JANX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-18.44x
Industry
-108.97x
Market
31.36x
JANX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.46x
Industry
4.66x
JANX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
JANX's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.5M
Profit Margin
0%
JANX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
JANX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.1B
Liabilities
$38.3M
Debt to equity
0.04
JANX's short-term assets ($1.02B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JANX's short-term assets ($1.02B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JANX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.0M
Investing
-$340.4M
Financing
$554.0k
JANX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
JANX vs Biotech Stocks
Janux Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.